Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

THE DOSING STORY:

ONE FDA-approved treatment, ONE small capsule, ONE daily dose1

Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

NUPLAZID® (pimavanserin) 34mg Bottle Image

Confidently prescribe NUPLAZID® (pimavanserin) 34 mg, single once-daily capsule, for appropriate patients with hallucinations and delusions associated with PD psychosis.1

FDA Approved

ONE FDA-approved treatment1

  • The only FDA-approved therapy proven to reduce the frequency and/or severity of hallucinations and delusions associated with PD psychosis in elderly patients without impacting motor function
    • In the 6-week studies, 80% of patients were aged 65 years or older*

In the clinical studies, the maximum age of patients on NUPLAZID was 85 years old vs 90 years old for placebo.2

Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)

 

ONE small capsule

  • 34 mg in one single capsule

Actual size is 14.3 mm x 5.3 mm.

One Daily Dose
 

ONE daily dose

  • Taken orally with or without food, without titration
  • No dosage adjustment of carbidopa/levodopa is required when administered concomitantly with NUPLAZID
  • Avoid the use of NUPLAZID in combination with other drugs known to prolong the QT interval
  • For patients taking strong CYP3A4 inhibitors, the recommended dose of NUPLAZID is 10 mg once daily
  • Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID
  • NUPLAZID does not require a dosage adjustment in elderly patients, patients with mild to severe renal impairment or end-stage renal disease (ESRD),§ or in patients with hepatic impairment

In clinical studies, NUPLAZID prolonged the QT interval (mean increase ~5-8 ms).1

Increased exposure (Cmax and AUC) to NUPLAZID occurred in patients with severe renal impairment (CrCl <30 mL/min, Cockcroft-Gault) in a renal impairment study, NUPLAZID should be used with caution in patients with severe renal impairment and ESRD.1

 

The steady-state plasma concentration of NUPLAZID was reached in ~12 days with continuous treatment, without titration2

Simulation of a Typical Concentration Profile of Once-daily NUPLAZID® (pimavanserin) 34 mg, Graph
  • Half-life (t1/2) is 57 hours1
 
NUPLAZIDconnect™ Logo

NUPLAZIDconnect™ makes it easy to get patients started on treatment.

For healthcare professionals